Broadly-neutralizing anti-HIV antibodies

Patent metadata

Field	Value
Publication number	US-11649276-B2
Application number	US-202117470184-A
Country	US
Kind code	B2
Filing date	Sep 9, 2021
Priority date	Oct 18, 2012
Publication date	May 16, 2023
Grant date	May 16, 2023

Abstract

The present invention relates to anti-HIV antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immunosuppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has led to the death of at least 25 million people worldwide.

First claim

The invention claimed is:

1. An isolated polynucleotide comprising a sequence encoding an anti-HIV antibody or antigen binding portion thereof, wherein the anti-HIV antibody or antigen binding portion comprises (i) a heavy chain variable region comprising CDRH 1, CDRH 2, and CDRH 3, wherein the CDRH 1, CDRH 2 and CDRH 3 comprise the respective sequences of SEQ ID NOs: 69-71, and (ii) a light chain variable region comprising CDRL 1, CDRL 2 and CDRL 3, wherein the CDRL 1, CDRL 2 and CDRL 3 comprise the respective sequences of SEQ ID NOs: 72-74.

2. A vector comprising the polynucleotide of claim 1 .

3. A cultured cell comprising the vector of claim 2 .

4. The isolated polynucleotide of claim 1 , wherein the heavy chain variable region comprises the sequence of SEQ ID NO: 13.

5. The isolated polynucleotide of claim 1 , wherein the light chain variable region comprises the sequence of SEQ ID NO: 14.

6. The isolated polynucleotide of claim 1 , wherein the heavy chain variable region and the light chain variable region comprise the respective sequences of SEQ ID NOs: 13-14.

7. The isolated polynucleotide of claim 1 , wherein the antibody is a human antibody, a humanized antibody, or a chimeric antibody.

Assignees

• Univ Rockefeller
• California Inst Of Techn

Inventors

• Mouquet Hugo
• Nussenzweig Michel
• Bjorkman Pamela J
• Scharf Louise

Classifications

• C07K16/1145

  Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site · CPC title

• C07K16/114 Primary

  Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV] · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• C12N2740/16111

  concerning HIV env · CPC title

• A61P31/18 Primary

  for HIV · CPC title